The first biologic indicated in CRSwNP1,2†

DUPIXENT® is a human monoclonal antibody that specifically binds to the IL-4Rα subunit shared by receptor complexes for IL-4 and IL-131†

Showing the mechanism of action of DUPIXENT. The image shows a type 2 receptor with IL-4Ra and IL-13Ra subunits. Above the receptor is the DUPIXENT monoclonal antibody, IL-4 and IL-13. DUPIXENT inhibits IL-4 and IL-13 signalling by binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes.”
Adapted from the Product Monograph.
 

IL-4 and IL-13 are key type 2 (including Th2) cytokines involved in atopic disease


ILC2: type 2 innate lymphoid cells; INCS: intranasal corticosteroids; Q2W: once every 2 weeks.
† Comparative clinical significance is unknown.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo